Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: Long-term results of a prospective, randomised, multicentre study

Eye

Volumn 23, Issue 11, 2009, Pages 2063-2070

  Birnbaum, Florian ^a   Mayweg, S ^b   Reis, A ^a   Bohringer D ^a   Seitz, B ^c   Engelmann, K ^d   Messmer, E M ^e   Reinhard, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b University Eye Hospital   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Eye Hospital   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

High risk keratoplasty; Immunosuppression; Mycophenolate mofetil

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; FLUOCORTOLONE; FLUOCORTOLONE CAPROATE; IMMUNOSUPPRESSIVE AGENT; INFLANEFRAN FORTE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; STEROID; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BLADDER CANCER; BLADDER CARCINOMA; BONE PAIN; BRONCHITIS; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; GRANULOCYTOSIS; HEADACHE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA; INSOMNIA; KAPLAN MEIER METHOD; KIDNEY COLIC; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NONHUMAN; OSTEALGIA; OTITIS; PARESTHESIA; PENETRATING KERATOPLASTY; PNEUMONIA; PROPHYLAXIS; PROSPECTIVE STUDY; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RAT; SIDE EFFECT; TACHYCARDIA; THRUSH; UROGENITAL TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES;

EID: 70450212557     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.402     Document Type: Article

References (37)

1. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- vs long-term therapy. Ophthalmology 1994; 101: 128-133.
2. Reinhard T, Hutmacher M, Sundmacher R. [Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk]. Klin Monatsbl Augenheilkd 1997; 210: 139-143. (Pubitemid 27407738)
3. Sundmacher R. [Allograft rejection reactions after keratoplasty (author's transl)]. Klin Monatsbl Augenheilkd 1977; 171: 705-722.
4. Birnbaum F, Bohringer D, Sokolovska Y, Sundmacher R, Reinhard T. Immunosuppression with cyclosporine a and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 2005; 79: 964-968.
5. Birnbaum F, Reis A, Böhringer D, Sokolowska Y, Mayer K, Voiculescu A et al. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006; 81: 767-772.
6. Reinhard T, Sundmacher R, Godehardt E, Heering P. [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. Ophthalmologe 1997; 94: 496-500.
7. Reinhard T, Reis A, Böhringer D, Malinowski M, Voiculescu A, Heering P et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001; 239: 367-372.
8. Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviefhaus H, Engelmann K et al. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int 2005; 18: 703-708.
9. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
10. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181-S190.
11. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659-1662.
12. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321-1325.
13. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: 391-396.
14. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029-1037.
15. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
16. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282-285.
17. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
18. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507-515.
19. Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. Transplant Proc 1998; 30: 4344-4347.
20. Reis A, Reinhard T, Sundmacher R, Braunstein C, Godehardt E. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 1998; 82: 700-703.
21. Sundmacher R, Reinhard T. Central corneolimbal transplantation under systemic ciclosporin A cover for severe limbal stem cell insufficiency. Graefes Arch Clin Exp Ophthalmol 1996; 234(Suppl 1): S122-S125.
22. Reinhard T, Sundmacher R. [Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin AFa retrospective study of 18 patients]. Klin Monatsbl Augenheilkd 1992; 201: 159-163.
23. Sundmacher R, Stefansson A, Mackensen G. [Postoperative course after keratoplasty]. Fortschr Ophthalmol 1983; 80: 224-227.
24. Hoffmann F. [Suture technique for perforating keratoplasty (author0s transl)]. Klin Monatsbl Augenheilkd 1976; 169: 584-590.
25. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99: 599-604.
26. Pleyer U, Weidle EG, Lisch W, Steuhl KP, Mohrle C, Richter U et al. [Clinical types of immunologic transplant reactions following perforating keratoplasty]. Fortschr Ophthalmol 1990; 87: 14-19.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Girard LJ, Esnaolo N, Rao R. Allograft rejection after penetrating keratoplasty for keratoconus. Ophthalmic Surg 1993; 24: 40-43.
29. Tompson RW, Price MO, Bowers PJ, Price FW. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003; 110: 1396-1402.
30. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989; 107: 506-510.
31. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 1996; 234(Suppl 1): S115-S121.
32. Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, Spelsberg H et al. Mycophenolate mofetil vs cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 1999; 83: 1268-1271.
33. Sundmacher R, Reinhard T, Heering P. Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective study. Ger J Ophthalmol 1992; 1: 432-436.
34. Reinhard T, Reis A, Kutkuhn B, Voiculescu A, Sundmacher R. [Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study]. Klin Monatsbl Augenheilkd 1999; 215: 201-202.
35. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047-2073.
36. Lake JR, David KM, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. Am J Transplant 2005; 5: 2961-2967.
37. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960.